Itraconazole and leishmaniasis: a randomised double-blind trial in cutaneous disease.
Cutaneous leishmaniasis (CL) is a vector-borne parasitic disease of the skin. Previous open controlled studies with oral itraconazole suggest that it was effective for CL in India. Twenty patients with localised CL participated in this trial. Patients were allocated randomly to receive capsule itraconazole and matching placebo for 6 weeks. No topical medicines were used. Demonstration of Leishmania by slit smear was mandatory. Prior to, periodically during and 3 months after completion of therapy an overall clinical assessment, liver function tests and urinalysis were performed. On decoding, out of the 10 cases receiving drug itraconazole, 7 were declared cured by clinical and parasitological criteria. No major side-effects were noted. Spontaneous remission was observed in 1 case in the placebo group at 3 months follow up. Oral itraconazole has a promising antileishmanial thus secure CL patient from the hazards of antimonials.
Dogra
J
J
C.G.H.S. Jaipur, India.
Saxena
V N
VN
D000981:Antiprotozoal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D007194:India; D017964:Itraconazole / Q000009:adverse effects / Q000627:therapeutic use*; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy*; D008111:Liver Function Tests
D000981:Antiprotozoal Agents; D017964:Itraconazole